Clinical Trial Update: Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Lurbinectedin/Doxorubicin against CAV or Topotecan in small-cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CAV
• Lurbinectedin (PM01183)/Doxorubicin (lurbinectedin; doxorubicin)
• Topotecan (topotecan)

Snippet

Sponsor: PharmaMar | Conditions: Small-cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-10-28